Medscape
A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author Nancy Lin, MD, presented these primary results of the DESTINY-Breast12 trial at the European Society for Medical Oncology Congress 2024. These findings were published simultaneously in the journal Nature Medicine. …
Read More
T-DXd Effective in Some With HER2+ Breast Cancer
A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author Nancy Lin, MD, presented these primary results of the DESTINY-Breast12 trial at the European Society for Medical Oncology Congress 2024. These findings were published simultaneously in the journal Nature Medicine. …